How to Cite IWQOL-Lite-Clinical Trials Version©

Kolotkin RL, Williams VSL, Ervin CM, Williams N, Meincke HH, Qin S, von Huth Smith L, Fehnel SE. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Clin Obes. 2019 Jun;9(3):e12310. doi: 10.1111/cob.12310.

​
​Development and Validation of the IWQOL-Lite-CT

Kolotkin, R.L., Ervin, C.M., Meincke, H.H., Højbjerre L., Fehnel, S.E. Development of a clinical trials version of the Impact of Weight on Quality of Life-Lite questionnaire (IWQOL-Lite Clinical Trials Version): Results from two qualitative studies. Clinical Obesity, 2017 Oct;7(5):290-299. doi: 10.1111/cob.12197.
​
Kolotkin, R.L., Williams, V.S.L., Ervin, C.M., Williams, N., Meincke, H.H., Qin, S., von Huth Smith, L., Fehnel, S.E. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Clinical Obesity, 2019 Jun;9(3):e12310. doi: 10.1111/cob.12310. View supporting tables for this publication.
​
Kolotkin, RL, Williams, VSL, von Huth Smith, L, et al. Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life–Lite Clinical Trials Version (IWQOL-Lite-CT). Clinical Obesity. 2021 Jul 22:e12477. doi: 10.1111/cob.12477.

IWQOL-Lite-CT Publications

Kolotkin, RL, Bushmakin, AG, Liu-Péré, N, Cappelleri, JC, Martin, S, Swan, JT, Luo, X. PCR153 Meaningful within-patient change of the IWQOL-Lite-CT physical function composite in adults with obesity. Value in Health, 2025-12-01, Volume 28, Issue 12, Pages S577-S578

Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, Aberle J, Bain SC, Allen S, Sarker E, Wu Q, Stefanski A, Jouravskaya I; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026 Dec 20;406(10522):2927-2944. doi: 10.1016/S0140-6736(25)02165-8. Epub 2025 Nov 20. PMID: 41275875.

Kanu C, Kimel M, Clucas C, Goetz I, Neff LM, Boye KS, Karn H. Psychometric Validation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity or Overweight. Adv Ther. 2025 Dec 24. doi: 10.1007/s12325-025-03460-9. Epub ahead of print. PMID: 41442025.

Brenisin K, Kinnafick F, King J, Millard L, Arya D, Hodgson E, Huggins M, Simmons-Roberts A, O'Dowd M, Rayment N, Shah P, Breen K
The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study. JMIR Res Protoc 2025;14:e76013
URL: https://www.researchprotocols.org/2025/1/e76013
DOI: 10.2196/76013

Hurtado, MD, Dunsmoor-Su, R, Huvinen, E, Rathor, N, Santoro, N, Wilson, L, Yaganti, S, Palacios, S. Impact of semaglutide 2.4 mg and oral semaglutide 25 mg on QoL in women with obesity: A post hoc analysis of the STEP and OASIS programs by menopausal status. Poster 77. Presented at The Menopause Society 2025 Annual Meeting, October 21–25 2025, Orlando, FL, USA.

Rubino, D, Birkhan, O, Garvey, WT, Lingvay, I, Rathor, N, Shaki, C, Wharton, S. Efficacy of oral semaglutide 25 mg in people with overweight or obesity and poor physical function. Poster 111. Presented at Obesity Week/The Obesity Society, November 4-7, Atlanta, GA, USA.

Li X, Cao D, Sapin H, Wang F, Hunter Gibble T, Raibulet NK, Denning M, Kaplan LM. People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment. Obesity (Silver Spring). 2025 Nov 4. doi: 10.1002/oby.70067. Epub ahead of print. PMID: 41187013.

Gibble TH, Cao D, Murphy M, Jouravskaya I, Liao B, Bays HE. Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4. Obesity (Silver Spring). 2025 Nov;33(11):2076-2092. doi: 10.1002/oby.70011. Epub 2025 Sep 3. PMID: 40903801.

Schnitzer, TJ, Hoffman, H, Brumm, JF, Forrester, TD, Mody, R, Falcon, B, Zakharyan, A, Gibble, TM. SAT-736 Post-hoc analysis of weight reduction and physical function in participants with obesity or overweight and osteoarthritis in SURMOUNT-1. Journal of the Endocrine Society, 2025, Volume 9 (supplement 1), https://doi.org/10.1210/jendso/bvaf149.592. 

Kamar, M, Ryan, DH, Leonard, S, Wyatt, HR, Kenan, Y, Asaraf, LC, Ganon-Elazar, E, Ard, JA. The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: the ELECT extension study, Obesity Pillars, 2025, 100216, ISSN 2667-3681, https://doi.org/10.1016/j.obpill.2025.100216. In press. (https://www.sciencedirect.com/science/article/pii/S2667368125000609).

Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2025;1‐11. doi:10.1111/dom.70209

Purcell AR, Rodrigo N, Longfield MSG, Glastras SJ. Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol. BMJ Open. 2025 Sep 16;15(9):e093775. doi: 10.1136/bmjopen-2024-093775. PMID: 40962353; PMCID: PMC12443176.

Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, Shaji C, Rubino D, Garvey WT; OASIS 4 Study Group. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025 Sep 18;393(11):1077-1087. doi: 10.1056/NEJMoa2500969. PMID: 40934115.
 
Kushner, R.F., Ard, J.D., Wadden, T.A. et al. Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01910-6
 
Kadowaki T, Heftdal LD, Ko HJ, Overvad M, Shimomura I, Thamattoor UK, Kim KK; OASIS 2 Investigators. Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. JAMA Intern Med. 2025 Aug 4:e253599. doi: 10.1001/jamainternmed.2025.3599. Epub ahead of print. PMID: 40758358; PMCID: PMC12322823.
 
Tadese BK, Hennessy F, Holbrook T, Prajapati G. Weight gain and health-related quality of life in people living with HIV on antiretroviral therapy in the United States. AIDS Care. 2025 Aug;37(8):1283-1291. doi: 10.1080/09540121.2025.2534116. Epub 2025 Jul 29. PMID: 40726406.
 
Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH; for the REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393:635-647. DOI: 10.1056/NEJMoa2502081.  
 
Galindo RJ, Lee CJ, Allen SE, Dib A, Boye KS, Thieu VT, Dong W, Sapin H, Wiese RJ. Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide. Diabetes Obes Metab. 2025 Oct;27(10):5694-5705. doi: 10.1111/dom.16620. Epub 2025 Jul 24. PMID: 40707399; PMCID: PMC12409245.
 
Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, Huang C, Lian Q, Yuan M, Gao G, Lu Y, Han J, Fu W, Wang H, Zhang Y, Shi X, Wen B, Shi B, Hu W, Guo T, Xing Y, Li Y, Li Q, Zheng Q, Yang M, Ning J, Guo M, Li Y, Pan H. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025 Sep;13(9):777-789. doi: 10.1016/S2213-8587(25)00141-X. Epub 2025 Jun 21. PMID: 40555243.
 
Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD; for the REDEFINE 2 Study Group. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med 2025;393:648-659. DOI: 10.1056/NEJMoa2502082.
 
Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, Ajaz Hussain S, Pedersen SD, Borowska L, Unseld A, Kloer IM, Kaplan LM; SYNCHRONIZE‐1 and ‐2 trial committees and investigators. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Obesity (Silver Spring). 2025 Jan;33(1):67-77. doi: 10.1002/oby.24184. Epub 2024 Nov 4. PMID: 39495965; PMCID: PMC11664303.
 
Kasagga A, Assefa A, Amin M N, et al. (June 07, 2025) Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Cureus 17(6): e85531. doi:10.7759/cureus.8553
 
Hunter Gibble, T., Cao, D., Zhang, X.M. et al. Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial. Diabetes Ther 16, 977–991 (2025). https://doi.org/10.1007/s13300-025-01723-w.
 
Gudzune KA, Stefanski A, Cao D, Mojdami D, Wang F, Ahmad N, Ling Poon J. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study. Diabetes Obes Metab. 2025 Feb;27(2):539-550. doi: 10.1111/dom.16046. Epub 2024 Nov 4. PMID: 39497468; PMCID: PMC11701187.
 
Katzmarzyk, PT, Price-Haywood, EG, Apolzan, JW, et al. Improving weight loss and cardiometabolic risk in black patients with diabetes or pre-diabetes: Rationale and protocol for a digital medicine hybrid type 1 implementation trial. Contemporary Clinical Trials, 2025, 107806, ISSN 1551-7144.
 
Goetz IA, Sutter C, Abraham T, Kanu C, Boye KS, Symonds T. The evaluation of clinical outcomes assessments and digital health technologies in clinical trials for obesity. J Patient Rep Outcomes. 2025 Feb 20;9(1):23. doi: 10.1186/s41687-025-00841-0. PMID: 39976863.  
 
Ibsen, C. K., Brostrøm Kousgaard, M., Olsen, S., Christiansen, A. K. L., Sandholdt, C. T., Rørth, R., & Overbeck, G. (2025). Patients’ experiences with GLP1-RAs – a systematic review. Scandinavian Journal of Primary Health Care, 1–10.  
 
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025 Mar 6;392(10):958-971. doi: 10.1056/NEJMoa2410819. Epub 2024 Nov 13. PMID: 39536238.
 
Hamza M, Papamargaritis D, Davies MJ. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2025 Jan;26(1):31-49. doi: 10.1080/14656566.2024.2436595. Epub 2024 Dec 4. PMID: 39632534.
 
Pérez-Piñero, S.; Muñoz-Carrillo, J.C.; Echepare-Taberna, J.; Herrera-Fernández, C.; Muñoz-Cámara, M.; Ávila-Gandía, V.; López-Román, F.J. Efficacy of a Dietary Supplement Extracted from Persimmon (Diospyros kaki L.f.) in Overweight Healthy Adults: A Randomized, Double-Blind, Controlled Clinical Trial. Foods 2024, 13, 4072.
 
Gibble TM, Cao D, Murphy M, Jouravskaya, I, Liao, B. 5184 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-4 phase 3 Trial, Journal of the Endocrine Society, Volume 8, Issue Supplement_1, October-November 2024, bvae163.044,   
 
Gibble TM, Cao D, Murphy M, Jouravskaya I, Liao B. 5183 Tirzepatide Improved Health-Related Quality of Life in People with Obesity or Overweight: Results from SURMOUNT-4 Phase 3 Trial, Journal of the Endocrine Society, Volume 8, Issue Supplement_1, October-November 2024, bvae163.042,  
 
Gibble, TM, Cao D,  Forrester, TD, Brumm, JF. 8366 Weight Reduction is Associated with Improved Quality of Life in Patients in SURMOUNT-3, Journal of the Endocrine Society, Volume 8, Issue Supplement_1, October-November 2024, bvae163.053,
 
Hunter Gibble, T., Cao, D., Zhang, M.X., Xavier, N.A., Poon, J.L.; 1700-P: Weight Reduction Is Associated with Improved Quality of Life in Participants with Obesity or Overweight and Type 2 Diabetes—Results from Phase 3 SURMOUNT-2 Trial. Diabetes 14 June 2024; 73 (Supplement 1): 1700–P.
 
Hunter Gibble, T., Cao, D., Forrester, T.D., et al.; 1676-P: Tirzepatide Improved Mental and Psychosocial Function in Adults with Obesity or Overweight in the SURMOUNT-3 Trial. Diabetes 14 June 2024; 73 (Supplement 1): 1676–P.
 
Goetz, I.A., Sutter, C., Abraham, T.H., Kanu, C., Boye, K., Symonds, T.; 1695-P: The Evaluation of Clinical Outcomes Assessments and Digital Health Technologies in Obesity Clinical Trials. Diabetes 14 June 2024; 73 (Supplement 1): 1695–P.
 
Sacher PM, Fulton E, Rogers V, Wilson J, Gramatica M, Dent JE, Aarts EO, Eccleston D, Greve JW, Palm-Meinders I, Chuttani R. Impact of a Health Coach–Led, Text-Based Digital Behavior Change Intervention on Weight Loss and Psychological Well-Being in Patients Receiving a Procedureless Intragastric Balloon Program: Prospective Single-Arm Study. JMIR Form Res 2024;8:e54723.
 
Zhao L, Cheng Z, Lu Y, Liu M, Chen H, Zhang M, Wang R, Yuan Y, Li X. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024 Aug 20;332(7):551-560. doi: 10.1001/jama.2024.9217. Erratum in: JAMA. 2024 Aug 20;332(7):595. doi: 10.1001/jama.2024.12249. PMID: 38819983; PMCID: PMC11337071.
 
Roza JM, Srivastava S. Effect of SophorOx® on Oxidative Stress and Body Composition in Individuals with High BMI: A Randomized Controlled Trial.  Diabetes Metab Syndr Obes. 2024;17:2221-2234.
 
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
 
Mu Y, Bao X, Eliaschewitz FG, Hansen MR, Kim BT, Koroleva A, Ma RCW, Yang T, Zu N, Liu M; STEP 7 Study Group. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024 Mar;12(3):184-195. doi: 10.1016/S2213-8587(23)00388-1. Epub 2024 Feb 5. PMID: 38330988.
 
Rubino D, Bjorner JB, Rathor N, Sharma AM, von Huth Smith L, Wharton S, Wadden T, Zeuthen N, Kolotkin RL. Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials. Diabetes Obes Metab. 2024 Jul;26(7):2945-2955. doi: 10.1111/dom.15620. Epub 2024 May 2. Erratum in: Diabetes Obes Metab. 2025 Mar;27(3):1631. PMID: 38698650.
 
Wadden, T.A., Chao, A.M., Machineni, S. et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023 Nov;29(11):2909-2918. doi: 10.1038/s41591-023-02597-w. Epub 2023 Oct 15. Erratum in: Nat Med. 2024 Jun;30(6):1784. doi: 10.1038/s41591-024-02883-1. PMID: 37840095; PMCID: PMC10667099.
 
Boye KS, Sapin H, Dong W, Williamson S, Lee CJ, Thieu VT. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide. Diabetes Ther. 2023 Nov;14(11):1867-1887. doi: 10.1007/s13300-023-01457-7. Epub 2023 Sep 5. PMID: 37668888; PMCID: PMC10570229.   
 
Poon, JL, Zhang, S, Kan, H, Bunck, MC, Dunn, J, Stefanski, A, Murphy, M. OR10-05 Improved Mental And Psychosocial Patient-Reported Outcomes Among People With Obesity Treated With Tirzepatide: Results From SURMOUNT-1 Study, Journal of the Endocrine Society, Volume 7, Issue Supplement_1, October-November 2023, bvad114.011.
 
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. PMID: 37385275.  
 
Boye, K.S., Thieu, V.T., Sapin, H. et al. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme. Diabetes Ther (2023).
 
Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 26;402(10403):705-719. doi: 10.1016/S0140-6736(23)01185-6. Epub 2023 Jun 26. PMID: 37385278.\
 
Gelhorn HL, Maher S, Sapin H, Poon JL, Boye K. Estimating meaningful change for The Impact of Weight on Self-Perception (IW-SP) questionnaire among people with type 2 diabetes. Qual Life Res. 2023 Dec;32(12):3359-3371. doi: 10.1007/s11136-023-03476-0. Epub 2023 Jul 25. PMID: 37491582; PMCID: PMC10624730.
 
Kolotkin, RL, Jeppesen, OK, Baker-Knight, J, Lee, SY, Tokita, A, Kadowaki, T. Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial. Clinical Obesity. 2023; 13(4):e12589. doi:10.1111/cob.12589.  
 
Zhang R, Hou QC, Li BH, Deng L, Yang YM, Li TX, Yao XQ, Yang LL, Lin XL, Liao YQ, Wang L, Liu YP, Tan J, Wan ZW, Shuai P. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023 Jun 26;14:1132004. doi: 10.3389/fendo.2023.1132004. PMID: 37455913; PMCID: PMC10338217.
 
Poon, JL., Marshall, C., Johnson, C. et al. A qualitative study to examine meaningful change in physical function associated with weight-loss. Qual Life Res 32, 1329–1340 (2023).
 
Lee, C, Boye, K, Thieu, V, Allen, S, Dong, W, Sapin, H. 752-P: Improved BMI Category Is Associated with Better Patient-Reported Outcomes (PROs) in Adults with T2D Treated with Tirzepatide. Diabetes 20 June 2023; 72 (Supplement_1): 752–P.
 
Boye, K, Thieu, V, Yu, M, Sapin, H. Higher weight loss is associated with improved quality of life in patients with type 2 diabetes—SURPASS program. Diabetes 2022;71(Supplement_1):47-LB.
 
Boye, KS, Yu, M, Liu, B, et al. Patient reported outcomes for tirzepatide versus semaglutide in participants with T2D from the SURPASS-2 Trial. Diabetes Research and Clinical Practice. Volume 186; Supplement 1, 109697, April 01, 2022.
 
le Roux CW, Zhang S, Aronne LJ, et al. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2022;1‐15. doi:10.1002/oby.23612
 
Toliver J, Watkins S, Byrne K, Oh J. PCR95 Functional Quality of Life Among People Living With Obesity: A Longitudinal Cohort of Patient Reported Outcomes. Value in Health. 2022;25:S408.​
 
Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. doi: 10.1016/S2213-8587(22)00008-0. Epub 2022 Feb 4. PMID: 35131037.
 
O'Neil PM, Rubino DM. Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. Postgrad Med. 2022 Jan;134(sup1):28-36. doi: 10.1080/00325481.2022.2150006. PMID: 36691307.
 
Kolotkin, RL, Williams, VSL, von Huth Smith, L, et al. Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life–Lite Clinical Trials Version (IWQOL-Lite-CT). Clinical Obesity. 2021 Jul 22:e12477. doi: 10.1111/cob.12477.
 
Rubino, DM, Færch, L, Meincke, H, et al. (2021). 84OR: Semaglutide 2.4 mg Improves Health-Related Quality of Life in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial. Diabetes 1 June 2021; 70 (Supplement_1): 84–OR. https://doi.org/10.2337/db21-84-OR.
 
Wharton, S, Meincke, HH, Kushner, RF, Oral, TK, Pedersen, S, Rubino, D, Ryan, DH, Zeuthen, N, Kolotkin, RL. 85-OR: Semaglutide 2.4 mg Improves Patient Reported Outcome Measures of Physical Functioning in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial. Diabetes 1 June 2021; 70 (Supplement_1): 85–OR.
 
Wharton, S, Bjorner, JB, Kushner, RF, et al. Semaglutide 2.4 mg Once Weekly Improves Patient-Reported Outcome Measures of Physical Functioning in Adults with Overweight or Obesity in the STEP 1 Trial. Obesity Facts; 2021;15 (suppl 1): 52-53.
 
Rubino, DM, Bjorner, JB, Kushner, RF, et al. Beneficial Effect of Semaglutide 2.4 mg Once Weekly on Patient-Reported Outcome Measures of Weight-Related and Health-Related Quality of Life in Adults with Overweight or Obesity in the STEP 1 Trial. Obesity Facts; 2021;15 (suppl 1): 118-119.
 
Wilding, JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; for the STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384 (11): 989-1002.
 
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; for the STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 2:S0140-6736(21)00213-0. doi: 10.1016/S0140-6736(21)00213-0.
 
Wadden, T.A., Tronieri, J.S., Sugimoto, D., Lund, M.T., Auerbach, P., Jensen, C., Rubino, D. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring). 2020 Mar;28(3):529-536. doi: 10.1002/oby.22726/.
 
Garvey, W.T., Birkenfeld, A.L., Dicker, D., et al. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 Mar 5. pii: dc191745. doi: 10.2337/dc19-1745.  
 
Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061. doi:10.1002/oby.22794
 
Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321 (15):1466–1480, Supplement 1.
 
Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17. PMID: 31530667; PMCID: PMC7364672.
 
Kolotkin, R.L., Williams, V.S.L., Ervin, C.M., Williams, N., Meincke, H.H., Qin, S., von Huth Smith, L., Fehnel, S.E. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Clinical Obesity, 2019 Jun;9(3):e12310. doi: 10.1111/cob.12310. View supporting tables for this publication.
 
Kolotkin, R.L., Ervin, C.M., Meincke, H.H., Højbjerre L., Fehnel, S.E. Development of a clinical trials version of the Impact of Weight on Quality of Life-Lite questionnaire (IWQOL-Lite Clinical Trials Version): Results from two qualitative studies. Clinical Obesity, 2017 Oct;7(5):290-299. doi: 10.1111/cob.12197.